Vitality Biopharma Developing Cannabis-derived Prodrugs for Inflammatory Bowel Disease

Vitality Biopharma Developing Cannabis-derived Prodrugs for Inflammatory Bowel Disease
Vitality Biopharma of California has developed a new class of cannabis-derived cannabinoid prodrugs, known as cannabosides, which can enable the selective delivery of cannabidiol (CBD), a cannabinoid compound, to the intestinal tract, and reduce the delivery of the psychoactive tetrahydrocannabinol (THC) to the brain. Vitality Biopharma, which is developing cannabinoid prodrug pharmaceuticals to treat neurological and inflammatory disorders, has

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *